Dr. Anne Bassett is a senior clinician scientist within the Schizophrenia Division and heads the Clinical Genetics Research Program at the Centre for Addiction and Mental Health (CAMH).
She holds the Dalglish Chair in 22q11.2 Deletion Syndrome at the University of Toronto and University Health Network (UHN), is a professor in the University of Toronto Department of Psychiatry and is a senior scientist at the Toronto General Hospital Research Institute, with cross-appointments in the Division of Cardiology and the Department of Mental Health at UHN. She received the 2020 Lieber Prize for Outstanding Achievement in Schizophrenia Research from the Brain and Behavior Research Foundation; only one other Canadian has received this honour.
Areas of Research
Dr. Bassett is an internationally renowned expert in the genetics of schizophrenia and other complex developmental disorders, including congenital cardiac disease. The goal of her research is to gain new insights into the mechanisms of illness that will enable development of novel treatment and prevention strategies. She is the principal investigator of studies that aim to understand the genetic architecture of schizophrenia and characterize clinically relevant genetic subtypes of schizophrenia. Dr. Bassett has pioneered studies of the first molecular subtype of schizophrenia; individuals with a 22q11.2 microdeletion. Dr. Bassett’s work has shown that about one in every 20 to 25 patients with schizophrenia has this or another clinically relevant genetic change that may be found with routine clinical testing. As a leader in Medical Psychiatry and translating genetic research findings directly into clinical practice, Dr. Bassett’s career embodies precision medicine, and includes teaching at all levels, as well as extensive public service.
Publications
View Dr. Bassett's publications on PubMed.